Barclays’s BeOne Medicines ONC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-30,400
Closed -$9.03M – 5709
2026
Q1
$9.03M Buy
30,400
+19,900
+190% +$6.44M ﹤0.01% 1511
2025
Q4
$3.19M Sell
10,500
-3,000
-22% -$982K ﹤0.01% 2592
2025
Q3
$4.6M Buy
+13,500
New +$4.1M ﹤0.01% 2267
2024
Q4
– Sell
-57,000
Closed -$12.8M – 5537
2024
Q3
$12.8M Buy
+57,000
New +$10.3M ﹤0.01% 1313
2024
Q1
– Sell
-15,000
Closed -$2.71M – 5426
2023
Q4
$2.71M Buy
+15,000
New +$2.71M ﹤0.01% 2665
2018
Q4
– Sell
-30,000
Closed -$5.17M – 7411
2018
Q3
$5.17M Buy
+30,000
New +$5.04M ﹤0.01% 1786

Other funds holding ONC

Barclays's ONC Position: Q3 2026 in Review

Barclays reduced its BeOne Medicines (ONC) stake by 27% in Q3 2026, selling an estimated $2.52M and leaving 20,335 shares worth $7.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1825.

Barclays first reported a position in ONC in Q4 2016 and has held it in 40 quarters since. The position peaked at $19.7M in Q4 2020. 325 funds tracked by Wall St. Rank hold ONC as of Q3 2026.

  • Barclays held 20,335 shares of BeOne Medicines worth $7.44M as of Q3 2026.
  • Barclays sold 7,381 BeOne Medicines shares in Q3 2026, an estimated $2.52M.
  • BeOne Medicines made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1825 holding.
  • Barclays first reported a position in BeOne Medicines in Q4 2016 and has held it in 40 quarters since.
  • Barclays's BeOne Medicines position peaked at $19.7M in Q4 2020.
  • 325 funds tracked by Wall St. Rank held BeOne Medicines as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.